Detalhe da pesquisa
1.
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.
Eur J Haematol
; 111(2): 300-310, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37321625
2.
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.
Am J Hematol
; 98(9): 1407-1414, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37421604
3.
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Blood
; 135(12): 912-920, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31978221
4.
Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study.
Br J Haematol
; 198(3): e46-e50, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608260
5.
Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.
Clin Pharmacol Ther
; 113(4): 904-915, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36660902
6.
Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial.
Contemp Clin Trials Commun
; 26: 100901, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35198796
7.
Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab.
Clin Med Insights Oncol
; 13: 1179554919852071, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31191068
8.
Tumor Static Concentration Curves in Combination Therapy.
AAPS J
; 19(2): 456-467, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27681102
9.
Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model.
Fundam Clin Pharmacol
; 28(2): 161-9, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23384250
10.
A template model for studying anticancer drug efflux transporter inhibitors in vitro.
Fundam Clin Pharmacol
; 27(5): 544-56, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22882086
11.
Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO.
J Geriatr Oncol
; 4(1): 48-57, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24071492